Immunoglobulin News and Research

RSS

Is one dose of Pfizer-BioNTech mRNA vaccine for COVID-19 convalescents sufficient?

Researchers evaluated the immune response in a cohort of 1,089 healthcare workers who received the Pfizer-BioNTech vaccine in Southern California.

26 Feb 2021

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

The first instance of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak in Austria was observed in the Ski resort Ischgl in early March 2020. Later, the virus spread across Austria and other countries in Northern Europe.

25 Feb 2021

Pre-existing cross-reactive HCoV antibodies could protect against SARS-CoV-2

A team of researchers from Spain and Canada recently characterized the antibody kinetics and neutralization capacity at 4 cross-sectional surveys between March and October 2020 and determined the seroprevalence in the same cohort of healthcare workers.

25 Feb 2021

Microbes could predict fatal outcomes in ventilated COVID-19 patients

The study "Microbial signatures in the lower airways of mechanically ventilated COVID19 patients associated with poor clinical outcome" is available as a preprint on the medRxiv* server, while the article undergoes peer review.

25 Feb 2021

SARS-CoV-2 ORF7a mutation limits host immune suppression, finds study

Researchers have identified a high variability in the C-terminal end of ORF7a in SARS-CoV-2 sequences collected from around the globe. They noted that mutations result in a defective suppression of interferon and lowered replication rate.

25 Feb 2021

Study shows antibody responses persisting 10 months after SARS-CoV-2 infection

Researchers in Italy have conducted a study showing that patients who had tested positive for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still had neutralizing antibodies against the virus 10 months later.

24 Feb 2021

TBE patients continue to be affected by long-term problems

Impaired memory, reduced motivation, and declining motor skills. These are some of the problems that may persist several years after people contract tick-borne encephalitis, a University of Gothenburg thesis shows.

23 Feb 2021

Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection?

Scientists at the University of Salzburg and Pantec Biosolutions AG have developed a laser-facilitated epicutaneous immunization against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The model has induced angiotensin-converting enzyme 2 (ACE2) blocking antibodies in mice.

23 Feb 2021

Countries with older populations have higher SARS-CoV-2 infections and deaths, says study

A new study examines some patterns revealed by a study of the factors operating in different regions and countries, to offer plausible hypotheses of these variations.

23 Feb 2021

Seropositive individuals show similar antibody levels to a second mRNA vaccine dose

Seropositive individuals —people who received antibodies after COVID-19 infection — may be able to safely delay their second mRNA vaccine dose after all, according to the results of a new study.

22 Feb 2021

An overview of spike protein antigen COVID-19 vaccine candidates

A new paper in the journal Reviews in Medical Virology provides a perspective on current vaccine development strategies and tools, which may allow the production of safe and effective vaccines.

22 Feb 2021

Study profiles the nose to predict immune response during COVID-19

SARS-CoV-2 resides in mucous membranes, making it easy to detect viral load in the nasal cavities. An international group of researchers has characterized the immunological and diagnosis characteristics of patients who may have or are confirmed with SARS-CoV-2 infection. The team found a distinct nasal cytokine profile that could help identify patients at risk for high inflammatory responses to SARS-CoV-2 infection.

22 Feb 2021

Llama-derived nanobodies show neutralizing activity against SARS-CoV-2 variants of concern in vitro

A new study reports the development of nanoantibodies (nAbs) – also called or nanobodiesTM or single-domain antibodies – that effectively bind the SARS-CoV-2 spike protein from the ancestral Wuhan variant as well as the recently detected UK and South African variants.

19 Feb 2021

Chicken-derived antibody shows potent neutralizing capacity against SARS-CoV-2 in vitro

Researchers report on a Chicken-derived antibody against SARS-CoV-2, offering preliminary data on a potential therapeutic for COVID-19 warranting further research.

19 Feb 2021

Domestic dogs unlikely to transmit SARS-CoV-2, say researchers

Researchers in Spain and Germany have conducted a study showing that domestic dogs are unlikely to contribute to the transmission and community spread of SARS-CoV-2 – the agent that causes COVID-19.

19 Feb 2021

Clinical trial launched to analyze bovine-derived immunoglobulins for preventing COVID-19 side effects

The Hospital del Mar Medical Research Institute (IMIM), Hospital del Mar, the University of California-Davis and the University of Texas have launched a clinical trial to analyze how useful a food supplement can be for preventing the worst side effects of COVID-19.

18 Feb 2021

SARS-CoV-2 D614G mutation associated with lower antibody binding

The onset of the COVID-19 pandemic has brought about an international effort to uncover the biology of its causative agent, SARS-CoV-2, and to develop effective and safe antivirals to contain and treat the infection. A new study by a team of researchers in France and Sweden discusses one such study, exploring the relative immunogenicity of the three main structural proteins of the virus.

18 Feb 2021

Clonally expanded plasma cell lineages in SARS-CoV-2 produce specific neutralizing antibodies

A new preprint research paper posted to the bioRxiv server provides a greater understanding of the aspect of humoral immunity against the virus – the plasma cells that pour out a flood of specific antibodies targeting various epitopes on the pathogen.

16 Feb 2021

Nanoparticle COVID-19 vaccine stimulates robust and long lasting immunity in primates

In the study, published on the preprint server bioRxiv, the team evaluated the ability of AS03, CpG 1018 formulated in Alum, the TLR-7 agonist adsorbed to Alum (AS37), the squalene-in-water emulsion (O/W), and Alum to boost protective immunity against SARS-CoV-2.

15 Feb 2021

Researchers observe rapid increase of SARS-CoV-2 antibodies in plasma over pandemic's course

Researchers found that neutralizing antibodies against SARS-CoV-2 can increase over time. They observed that samples taken from convalescent plasma in September 2020 would likely have high enough values by July 2021 to protect immunodeficient patients who receive intravenous immunoglobulins as part of their treatment.

15 Feb 2021

Immunoglobulin News and Research

Is one dose of Pfizer-BioNTech mRNA vaccine for COVID-19 convalescents sufficient?

Antibody and T cell response to SARS-CoV-2 persist up to 8 months: Study of Ski Resort Ischgl

Pre-existing cross-reactive HCoV antibodies could protect against SARS-CoV-2

Microbes could predict fatal outcomes in ventilated COVID-19 patients

SARS-CoV-2 ORF7a mutation limits host immune suppression, finds study

Study shows antibody responses persisting 10 months after SARS-CoV-2 infection

TBE patients continue to be affected by long-term problems

Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection?

Countries with older populations have higher SARS-CoV-2 infections and deaths, says study

Seropositive individuals show similar antibody levels to a second mRNA vaccine dose

An overview of spike protein antigen COVID-19 vaccine candidates

Study profiles the nose to predict immune response during COVID-19

Llama-derived nanobodies show neutralizing activity against SARS-CoV-2 variants of concern in vitro

Chicken-derived antibody shows potent neutralizing capacity against SARS-CoV-2 in vitro

Domestic dogs unlikely to transmit SARS-CoV-2, say researchers

Clinical trial launched to analyze bovine-derived immunoglobulins for preventing COVID-19 side effects

SARS-CoV-2 D614G mutation associated with lower antibody binding

Clonally expanded plasma cell lineages in SARS-CoV-2 produce specific neutralizing antibodies

Nanoparticle COVID-19 vaccine stimulates robust and long lasting immunity in primates

Researchers observe rapid increase of SARS-CoV-2 antibodies in plasma over pandemic's course

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News